Gavreto is FDA-approved for RET-altered thyroid cancers

By Brian Buntz | July 21, 2021

GAVRETO Blueprint Medicines FDA has indicated Gavreto (pralsetinib) from Blueprint Medicines to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).

The drug was formerly known as BLU-667 and won FDA approval in September 2020.

CStone, which is developing the drug in China, received approval from that country’s regulatory authority, making it the first novel therapy for locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy.

Filed Under: Oncology
Tagged With: BLU-667, Blueprint Medicines, GAVRETO, non-small cell lung cancer, pralsetinib

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].